• Viral RIPK3 Degradation and Inflammation

  2026-10-01

  Liu et al. identified a class of orthopoxvirus proteins that recruits host ubiquitin machinery to degrade RIPK3, thereby suppressing necroptosis while reshaping viral inflammation and pathogenicity. The study combines a targeted siRNA screen, viral genetics, biochemical validation, and mouse infection models to establish the vIRD–RIPK3 axis as an evolutionary determinant of virus–host interaction.

• 3-Dehydroteasterone Derivatives: Assay-Dependent Activity

  2026-10-01

  Valdés and co-workers developed benzoate-substituted 3-dehydroteasterone analogs and evaluated them with rice lamina inclination and bean second-internode bioassays. The study shows that side-chain architecture, aromatic substitution, and the choice of plant assay strongly influence apparent brassinosteroid activity.

• MDL 28170: Calpain Signaling in Assay Design

  2026-09-30

  MDL 28170 is a cell-permeable calpain inhibitor that helps dissect protease-driven neuronal injury, synaptic dysfunction, and cell death. This article translates recent BDNF/TrkB findings into practical assay decisions while distinguishing calpain effects from cathepsin B activity and downstream apoptosis.

• NF 449: Precision in P2X1 Platelet Biology

  2026-09-30

  NF 449 connects exceptionally potent P2X1 blockade with a translational framework for dissecting ATP-driven platelet activation, interpreting selectivity, and advancing antithrombotic agent research without confusing mechanistic promise with clinical proof.

• RIPA Lysis Buffer (Strong) in Glioma Assays

  2026-09-29

  Translate glioma pathway discoveries into practical Western blot, immunoprecipitation, and phosphoprotein workflows with a detergent-rich lysis strategy. This guide shows where RIPA Lysis Buffer (Strong) excels, when its strength can compromise protein complexes, and how to optimize sample handling for CSRP2–PDGFRA/PI3K/AKT validation.

• Meropenem Workflows for Carbapenem Resistance

  2026-09-29

  Meropenem supports reproducible susceptibility testing, resistance-mechanism mapping, and Gram-negative infection model development. This workflow connects antibacterial phenotype data with plasmid transmission evidence while emphasizing compound handling, assay controls, and research-only interpretation.

• Diphenyleneiodonium Chloride in Redox Assays

  2026-09-28

  Diphenyleneiodonium chloride helps dissect NOX-linked redox changes while also enabling GPR3-related cAMP signaling experiments. This workflow-focused guide shows how to separate enzyme inhibition, receptor pharmacology, and time-dependent Nrf2 responses for more defensible oxidative stress research.

• APEX2 Supports TERT Expression in Human Stem Cells

  2026-09-28

  A 2024 preprint reports that APEX2, unlike its paralog APEX1, is needed for efficient TERT expression and telomerase activity in human embryonic stem cells, with related findings in a melanoma cell line. RNA-seq and chromatin immunoprecipitation point to repetitive DNA regions as candidate sites linking APEX2-dependent DNA repair with gene expression, although the mechanism remains to be tested.

• Brefeldin A (BFA): Practical Assay Design

  2026-09-27

  A scenario-based guide to using Brefeldin A (SKU B1400) in cell viability, trafficking, ER-stress, and apoptosis experiments. It distinguishes product-reported parameters from workflow recommendations and explains how to interpret results without over-attributing effects.

• Dye Models Improve Visibility of Small Biopsies

  2026-09-26

  Nonsiri and colleagues compared five dyes as visibility aids for very small tissue samples during routine pathology preparation. Their findings identify hematoxylin as a practical option: it improved sample observability while avoiding the diagnostic interference and toxicity concerns that favored it over merbromin and alcian blue.

• VE-821 Workflows for ATR Checkpoint Research

  2026-09-25

  Use VE-821 to interrogate ATR–Chk1 checkpoint signaling, radiosensitization, and chemotherapy response with a workflow built around target engagement and matched controls. A recent human bocavirus study offers a useful epigenetic comparison—but does not test VE-821 or establish ATR as a regulator of viral replication.

• Verapamil HCl: From Channel Blockade to Translation

  2026-09-25

  Verapamil HCl is more than a calcium-channel probe: it can help researchers interrogate excitability, cell-death responses, inflammation, and drug-efflux effects. This article separates what the evidence supports from what still needs testing—and offers a translational framework for designing interpretable studies.

• RapaLink-1: Choosing the Right mTOR Assay

  2026-09-24

  RapaLink-1 is a third-generation mTOR inhibitor with a distinctive dual-engagement design. This article explains how to interpret its cancer-model evidence and why pathway inhibition alone is not enough to claim embryonic dormancy.

• AMPK Causality in Metabolic Research: Dorsomorphin 2HCl

  2026-09-24

  A translational perspective on using Dorsomorphin 2HCl to test AMPK dependence in metabolic models—while accounting for its BMP activity, designing stronger controls, and avoiding overinterpretation of pharmacological inhibition.

• Thioguanine: Reading Assays Without Confusing Endpoints

  2026-09-23

  Thioguanine is studied as an antitumor and antiviral compound, but its relationship to 6-thioguanine selection assays is easy to misinterpret. This article separates drug pharmacology from mutation detection and shows how a glutaraldehyde toxicology study can inform assay design without being mistaken for direct evidence about thioguanine.

8632 records 1/576 page Next 12345 下5页 Last page